Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Buy” by Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have earned an average rating of “Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have covered the stock in the last year is $89.86.

A number of research firms have recently weighed in on KROS. Truist Financial reissued a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Bank of America lowered their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Oppenheimer started coverage on Keros Therapeutics in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 price target for the company.

Keros Therapeutics Stock Up 1.0 %

Keros Therapeutics stock opened at $56.98 on Monday. The company’s 50-day moving average price is $48.35 and its two-hundred day moving average price is $53.38. The stock has a market cap of $2.06 billion, a P/E ratio of -11.06 and a beta of 1.22. Keros Therapeutics has a twelve month low of $27.02 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter last year, the firm earned ($1.27) earnings per share. Equities analysts anticipate that Keros Therapeutics will post -4.78 earnings per share for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

Hedge funds have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics during the 2nd quarter worth approximately $128,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares during the period. Quest Partners LLC grew its stake in shares of Keros Therapeutics by 23,945.0% in the second quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock worth $220,000 after purchasing an additional 4,789 shares during the last quarter. XTX Topco Ltd acquired a new stake in Keros Therapeutics in the second quarter valued at $228,000. Finally, Bayesian Capital Management LP bought a new position in Keros Therapeutics during the 1st quarter worth $267,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.